Reports from V.A. Nasonova Research Institute of Rheumatology Advance Knowledge in Giant Cell Arteritis (Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6).

Researchers at the V.A. Nasonova Research Institute of Rheumatology have advanced knowledge in the treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (RPM) by exploring the use of monoclonal antibodies to interleukin 6. These immune-mediated rheumatic diseases typically affect individuals over 50 years old and are now considered part of a single complex autoimmune-autoinflammatory pathology. The study highlights the potential of biologic agents, such as tocilizumab, in targeting cytokines involved in the immunopathogenesis of these diseases, offering new prospects for therapy. The research emphasizes the need to optimize glucocorticoid therapy and explores the effectiveness and safety of IL-6 inhibitors in GCA and RPM, paving the way for further investigation in this field. [Extracted from the article]

Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)